Eltrombopag

Generic Name: Eltrombopag

Brand Names: Promacta, Revolade

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₂N_₄O_₄

CAS Number: 496775-61-2

Unique Ingredient Identifier: S56D65XJ9G

Background: Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also bee...

Indication: Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.

Associated Conditions: Chronic immune thrombocytopenia, Severe Aplastic Anemia (SAA), Thrombocytopenia

Associated Therapies: First-line Therapy

Clinical Trials

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Thrombocytopaenia

Interventions: Drug: eltrombopag
Drug: placebo

First Posted Date: 2011-09-26

Last Posted Date: 2017-06-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 162

Registration Number: NCT01440374

Locations: 🇹🇭
Novartis Investigative Site, Songkla, Thailand

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

Phase 3

Terminated

Conditions: Idiopathic Thrombocytopenic Purpura

Interventions: Drug: Avatrombopag
Drug: Eltrombopag
Drug: Standard of care

First Posted Date: 2011-09-14

Last Posted Date: 2018-02-06

Lead Sponsor: Eisai Inc.

Target Recruit Count: 24

Registration Number: NCT01433978

Locations: 🇺🇸
Prairie Lakes Health Care System, Watertown, South Dakota, United States

Drug Use Investigation for REVOLADE (ITP)

Completed

Conditions: Purpura, Thrombocytopaenic, Idiopathic

Interventions: Drug: Eltrombopag

First Posted Date: 2011-08-15

Last Posted Date: 2020-11-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5797

Registration Number: NCT01416311

Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)

Phase 1

Terminated

Conditions: Thrombocytopenia
Chronic Lymphocytic Leukemia

Interventions: Drug: Placebo
Drug: Eltrombopag

First Posted Date: 2011-07-19

Last Posted Date: 2015-05-28

Lead Sponsor: University of Ulm

Target Recruit Count: 4

Registration Number: NCT01397149

Locations: 🇦🇹
Medizinische Universität Wien, Innere Medizin I, Abt. Hämatologie und Hämastaseologie, Vienna, Austria
🇩🇪
Universitätsklinikum; Klinik für Hämatologie, Essen, Germany
🇩🇪
Universitätsklinikum Carl Gustav Carus Med. Klinik und Poliklinik I, Dresden, Germany

and more 7 locations

Eltrombopag for Moderate Aplastic Anemia

Phase 2

Active, not recruiting

Conditions: Unilineage Bone Marrow Failure Disorders
Moderate Aplastic Anemia

Interventions: Drug: Eltrombopag

First Posted Date: 2011-04-04

Last Posted Date: 2024-12-03

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 34

Registration Number: NCT01328587

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT

Early Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Eltrombopag

First Posted Date: 2011-01-31

Last Posted Date: 2019-03-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT01286675

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia

Phase 1

Terminated

Conditions: Thrombocytopenia
Myelodysplastic Syndrome (MDS)

Interventions: Drug: Eltrombopag

First Posted Date: 2011-01-31

Last Posted Date: 2022-11-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 37

Registration Number: NCT01286038

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Meta-analysis - Eltrombopag

Completed

Conditions: Thrombocytopaenia

Interventions: Drug: Placebo
Drug: Eltrombopag

First Posted Date: 2010-11-07

Last Posted Date: 2017-06-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT01235988

Indirect Comparison Between Eltrombopag & Romiplostim

Completed

Conditions: Thrombocytopaenia

Interventions: Drug: Romiplostim
Drug: Eltrombopag
Drug: Placebo

First Posted Date: 2010-11-07

Last Posted Date: 2017-06-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT01236014

Study of Eltrombopag in Platelet Refractory Thrombocytopenia

Phase 2

Withdrawn

Conditions: Thrombocytopenia

Interventions: Drug: Eltrombopag

First Posted Date: 2010-09-02

Last Posted Date: 2019-11-25

Lead Sponsor: University of Cincinnati

Registration Number: NCT01194167

Locations: 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy